Business Of Biotech

By: Matt Pillar
  • Summary

  • The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Bioprocess Online and Life Science Connect and brought to you by Cytiva.

    © 2024 Business Of Biotech
    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Biopolitics With Allan Shaw
    Nov 25 2024

    We love to hear from our listeners. Send us a message.

    The notion that political influence has no place in biology appears poised for a test it hasn’t studied for. Trump administration nominations, from RFK, Jr. to HHS and Vivek Ramaswamy to the newly-proposed DOGE, are driving a storm of speculation over the implications for biotech and other life sciences industries. Throw in the increased probability of the Biosecure Act seeing the light of legislation day under a republican congress, and there’s no shortage of biopolitical pontificating to be done. How might this all play out, and how should biotech builders be obviating? On this episode of the Business of Biotech, we’re joined for some reflection by none other than Allan Shaw.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
    50 mins
  • T-Cells For The Win With Adaptimmune's Adrian Rawcliffe
    Nov 18 2024

    We love to hear from our listeners. Send us a message.

    In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with unresectable or metastatic synovial sarcoma who have previously received chemotherapy. It marked the first new treatment for those patients in more than a decade; a win for those patients, and a win for Adrian Rawcliffe, who’s had a hand on the wheel at Adaptimmune, the therapy’s developer and manufacturer, since he joined the company as CFO in 2015. Today, Rawcliffe is CEO there, and on this episode of the Business of Biotech, we’re going to get to know him, why he’s all-in on cell therapies, and how he’s applying a solid track record in finance and business development to make good on the promise they offer.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
    1 hr and 2 mins
  • Serving The Underserved With Gates MRI's Claire Wagner, M.D.
    Nov 11 2024

    We love to hear from our listeners. Send us a message.

    On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there. She shares the development of her North Star while working with the incomparable Dr. Paul Farmer in Rwanda, and how that experience translates to the growth of a biopharmaceutical company taking big swings for grossly underserved populations. We discuss the nuances assoiated with setting strategy and enabling product access in a unique not-for-profit setting, and how, perhaps counterintutively, the Institute's work fits synergistically into an ultra-competitive for-profit biopharma landscape.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
    47 mins

What listeners say about Business Of Biotech

Average customer ratings
Overall
  • 3 out of 5 stars
  • 5 Stars
    0
  • 4 Stars
    0
  • 3 Stars
    1
  • 2 Stars
    0
  • 1 Stars
    0
Performance
  • 2 out of 5 stars
  • 5 Stars
    0
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    1
  • 1 Stars
    0
Story
  • 2 out of 5 stars
  • 5 Stars
    0
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    1
  • 1 Stars
    0

Reviews - Please select the tabs below to change the source of reviews.